Trial Profile
An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Aug 2020
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms PERFlexS
- Sponsors Janssen-Cilag
- 18 Jun 2020 Status changed from active, no longer recruiting to completed.
- 06 Mar 2020 Planned End Date changed from 31 Dec 2021 to 13 Mar 2020.
- 29 Jun 2018 Planned End Date changed from 31 Dec 2019 to 31 Dec 2021.